Literature DB >> 12960427

Gene expression patterns in ovarian carcinomas.

Marci E Schaner1, Douglas T Ross, Giuseppe Ciaravino, Therese Sorlie, Olga Troyanskaya, Maximilian Diehn, Yan C Wang, George E Duran, Thomas L Sikic, Sandra Caldeira, Hanne Skomedal, I-Ping Tu, Tina Hernandez-Boussard, Steven W Johnson, Peter J O'Dwyer, Michael J Fero, Gunnar B Kristensen, Anne-Lise Borresen-Dale, Trevor Hastie, Robert Tibshirani, Matt van de Rijn, Nelson N Teng, Teri A Longacre, David Botstein, Patrick O Brown, Branimir I Sikic.   

Abstract

We used DNA microarrays to characterize the global gene expression patterns in surface epithelial cancers of the ovary. We identified groups of genes that distinguished the clear cell subtype from other ovarian carcinomas, grade I and II from grade III serous papillary carcinomas, and ovarian from breast carcinomas. Six clear cell carcinomas were distinguished from 36 other ovarian carcinomas (predominantly serous papillary) based on their gene expression patterns. The differences may yield insights into the worse prognosis and therapeutic resistance associated with clear cell carcinomas. A comparison of the gene expression patterns in the ovarian cancers to published data of gene expression in breast cancers revealed a large number of differentially expressed genes. We identified a group of 62 genes that correctly classified all 125 breast and ovarian cancer specimens. Among the best discriminators more highly expressed in the ovarian carcinomas were PAX8 (paired box gene 8), mesothelin, and ephrin-B1 (EFNB1). Although estrogen receptor was expressed in both the ovarian and breast cancers, genes that are coregulated with the estrogen receptor in breast cancers, including GATA-3, LIV-1, and X-box binding protein 1, did not show a similar pattern of coexpression in the ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960427      PMCID: PMC266758          DOI: 10.1091/mbc.e03-05-0279

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  65 in total

1.  Clear cell carcinoma of the ovary.

Authors:  K Hameed; M R Burslem; W R Tupper
Journal:  Cancer       Date:  1969-09       Impact factor: 6.860

2.  Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer.

Authors:  R Halperin; S Zehavi; R Langer; E Hadas; I Bukovsky; D Schneider
Journal:  Int J Gynecol Cancer       Date:  2001 Sep-Oct       Impact factor: 3.437

3.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.

Authors:  C M Perou; S S Jeffrey; M van de Rijn; C A Rees; M B Eisen; D T Ross; A Pergamenschikov; C F Williams; S X Zhu; J C Lee; D Lashkari; D Shalon; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

4.  Serous papillary carcinomas arising from the peritoneum and ovaries. A clinicopathologic and immunohistochemical comparison.

Authors:  M R Wick; S E Mills; L P Dehner; D J Bollinger; R E Fechner
Journal:  Int J Gynecol Pathol       Date:  1989       Impact factor: 2.762

5.  Clear cell carcinoma of the ovary: a study of 59 cases.

Authors:  M A Crozier; L J Copeland; E G Silva; D M Gershenson; C A Stringer
Journal:  Gynecol Oncol       Date:  1989-11       Impact factor: 5.482

Review 6.  DNA microarrays for assessing ovarian cancer gene expression.

Authors:  Izhak Haviv; Ian G Campbell
Journal:  Mol Cell Endocrinol       Date:  2002-05-31       Impact factor: 4.102

7.  Identification by cDNA microarray of genes involved in ovarian carcinogenesis.

Authors:  K Ono; T Tanaka; T Tsunoda; O Kitahara; C Kihara; A Okamoto; K Ochiai; T Takagi; Y Nakamura
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

8.  Clinical picture of women with early stage ovarian cancer.

Authors:  G H Eltabbakh; P R Yadav; A Morgan; P R Yadev
Journal:  Gynecol Oncol       Date:  1999-12       Impact factor: 5.482

9.  Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma.

Authors:  R Halperin; S Zehavi; E Hadas; L Habler; I Bukovsky; D Schneider
Journal:  Int J Gynecol Pathol       Date:  2001-10       Impact factor: 2.762

10.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

View more
  115 in total

1.  The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.

Authors:  Daniel R Budman; Julia Tai; Anthony Calabro; Veena John
Journal:  Invest New Drugs       Date:  2010-06-09       Impact factor: 3.850

2.  Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression.

Authors:  Daniel R Rhodes; Jianjun Yu; K Shanker; Nandan Deshpande; Radhika Varambally; Debashis Ghosh; Terrence Barrette; Akhilesh Pandey; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

3.  Making sense out of massive data by going beyond differential expression.

Authors:  Patrick R Schmid; Nathan P Palmer; Isaac S Kohane; Bonnie Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-23       Impact factor: 11.205

4.  Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression.

Authors:  J Zhang; X Qin; Q Sun; H Guo; X Wu; F Xie; Q Xu; M Yan; J Liu; Z Han; W Chen
Journal:  Oncogene       Date:  2014-08-25       Impact factor: 9.867

5.  Telomere length and cancer mortality in American Indians: the Strong Heart Study.

Authors:  Pooja Subedi; Stefano Nembrini; Qiang An; Yun Zhu; Hao Peng; Fawn Yeh; Shelley A Cole; Dorothy A Rhoades; Elisa T Lee; Jinying Zhao
Journal:  Geroscience       Date:  2019-06-22       Impact factor: 7.713

6.  Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.

Authors:  Hector Alvarez; Pamela Leal Rojas; Ken-Tye Yong; Hong Ding; Gaixia Xu; Paras N Prasad; Jean Wang; Marcia Canto; James R Eshleman; Elizabeth A Montgomery; Anirban Maitra
Journal:  Nanomedicine       Date:  2008-08-08       Impact factor: 5.307

7.  Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

Authors:  Francois Moisan; Edgar B Francisco; Anamaria Brozovic; George E Duran; Yan C Wang; Shalini Chaturvedi; Shobha Seetharam; Linda A Snyder; Parul Doshi; Branimir I Sikic
Journal:  Mol Oncol       Date:  2014-04-18       Impact factor: 6.603

8.  NUCKS1 overexpression is a novel biomarker for recurrence-free survival in cervical squamous cell carcinoma.

Authors:  Lina Gu; Bairong Xia; Lili Zhong; Yuan Ma; Lei Liu; Liping Yang; Ge Lou
Journal:  Tumour Biol       Date:  2014-05-13

Review 9.  Pathogenesis of ovarian cancer: clues from selected overexpressed genes.

Authors:  Ie-Ming Shih; Ben Davidson
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

Review 10.  The antizyme family for regulating polyamines.

Authors:  Chaim Kahana
Journal:  J Biol Chem       Date:  2018-10-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.